论文部分内容阅读
目的探讨卵巢癌细胞及外周血淋巴细胞多药耐药基因(MDRI)表达产物P170的变化及临床意义。方法从38例首次手术及15例复发卵巢癌腹水中提取癌细胞(ACC),并抽静脉血提取淋巴细胞(PBL),用荧光单克隆抗体P170标记上述细胞,经流式细胞术检测。结果①化疗前21%卵巢癌组织P170阳性;②复发组ACC之MDR1表达明显高于初发组(P<0.05);③化疗期间PBL及ACC的MDR1,表达随疗程的增加均逐渐增高。结论卵巢癌细胞不仅可原发表达P170,且可随化疗疗程的增加而增加对P170的表达,通过流式分析PBL及ACC的P170含量可反映残余或复发卵巢癌细胞对化疗药物耐受的程度。
Objective To investigate the changes and clinical significance of the expression of multidrug resistance gene (MDRI) P170 in ovarian cancer cells and peripheral blood lymphocytes. Methods The tumor cells (ACCs) were extracted from 38 cases of primary surgery and 15 cases of recurrent ovarian ascites. The lymphocytes (PBLs) were extracted from venous blood and the cells were labeled with fluorescent monoclonal antibody P170 and detected by flow cytometry. Results ① The positive rate of P170 in 21% of ovarian cancer tissues before chemotherapy was significantly higher than that of the initial group (P <0.05). The expression of MDR1 in both PBL and ACC increased gradually during chemotherapy . Conclusions Ovarian cancer cells not only express P170, but also increase the expression of P170 with the increase of chemotherapy. The level of P170 in PBL and ACC can be analyzed by flow cytometry to reflect the degree of tolerance of residual or recurrent ovarian cancer cells to chemotherapeutic drugs .